You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

immunochemotherapy

Showing 1 - 25 of 201
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neoadjuvant Immunochemotherapy for Lung Cancer

Completed
  • Lung Cancer
  • Neoadjuvant immunochemotherapy
  • Shanghai, Shanghai, China
    Zhencong Chen
Sep 1, 2023

NLR and Its Association With Efficacy of Immunochemotherapy in

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Nov 10, 2023

    Rituximab, Lenalidomide, Zebutinib ,Mantle Cell Lymphoma Trial in Hangzhou (ZR2 RDHAP)

    Recruiting
    • Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
    • ZR2 RDHAP
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Aug 8, 2023

    Sequence and Time-of-day Infusion of immunoCHemotherapy Affect

    Completed
    • Esophagus Cancer
      • Guangzhou, Guangdong, China
        Guangdong Provincial People's Hospital
      Nov 24, 2022

      Pathological Tumor and Lymph Node Responses After Neoadjuvant

      Completed
      • Non Small Cell Lung Cancer
      • +3 more
      • Timing of drug administration
      • Guangzhou, Guangdong, China
        Guangdong Provincial People's Hospital
      Nov 24, 2022

      Immunochemotherapy in Esophageal Cancer

      Recruiting
      • Esophageal Cancer
        • Guangzhou, Guangdong, China
          Guangdong Provincial People's Hospital
        Nov 24, 2022

        HNSCC, Radiotherapy, PD-1 Trial in Guangzhou (PD-1inhibitor, concurrent chemoradiotherapy)

        Recruiting
        • HNSCC
        • +2 more
        • Guangzhou, Guangdong, China
          Sun yat-sen memorial hospital
        Aug 6, 2023

        Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy Trial in Guangzhou (drug, radiation, procedure)

        Recruiting
        • Esophageal Squamous Cell Carcinoma
        • +2 more
        • Guangzhou, Guangdong, China
          Guangdong Provincial People's Hospital
        Nov 24, 2022

        Breast Cancer Trial in Houston (Sacituzumab Govitecan, Pembrolizumab)

        Not yet recruiting
        • Breast Cancer
        • Houston, Texas
          M D Anderson Cancer Center
        Dec 22, 2022

        Neck Cancer Trial in Moscow (Pembrolizumab)

        Recruiting
        • Neck Cancer
        • Moscow, Russian Federation
        • +2 more
        Sep 21, 2022

        Minimally Residual of Esophageal Cancer 001

        Recruiting
        • Esophageal Carcinoma
        • Minimal Residual Disease
          • Shijiazhuang, Hebei, China
            Fourth Hospital of Hebei Medical University
          Jul 17, 2023

          Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

          Recruiting
          • Non-Small Cell Lung Cancer
          • Neoadjuvant immunochemotherapy
          • Neoadjuvant chemotherapy
          • Beijing, Beijing, China
            National Cancer Center/Cancer Hospital,Chinese Academy of Medica
          Aug 1, 2023

          Muscle-Invasive Bladder Carcinoma Trial in Philadelphia (AMVAC + Nivolumab)

          Recruiting
          • Muscle-Invasive Bladder Carcinoma
          • AMVAC + Nivolumab
          • Philadelphia, Pennsylvania
            Fox Chase Cancer Center - Philadelphia
          Apr 1, 2022

          CNS Lymphoma Trial in Aarhus (Immunochemo)

          Completed
          • Central Nervous System Lymphoma
          • Immunochemotherapy
          • Aarhus, Denmark
            Elisa Jacobsen Pulczynski
          Aug 3, 2022

          Diffuse Large B Cell Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Zanubrutinib and RCHOP)

          Not yet recruiting
          • Diffuse Large B Cell Lymphoma
          • Rituximab, Lenalidomide, Zanubrutinib and RCHOP
          • Hangzhou, Zhejiang, China
            Zhejiang Cancer Hospital
          Mar 21, 2022

          NSCLC Stage III Trial (radiotherapy, Platinum-Based Drug, Immunotherapy)

          Not yet recruiting
          • Non-small Cell Lung Cancer Stage III
          • radiotherapy
          • +3 more
          • (no location specified)
          Sep 10, 2023

          NSCLC Metastatic Trial (Atezolizumab, Nab paclitaxel, Carboplatin)

          Not yet recruiting
          • Non-Small Cell Lung Cancer Metastatic
          • (no location specified)
          Jan 18, 2023

          Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma Trial in Shanghai

          Recruiting
          • Esophageal Squamous Cell Carcinoma
          • +2 more
          • LDRT+CFRT
          • +2 more
          • Shanghai, China
          • +1 more
          Aug 3, 2023

          Esophageal Cancer, Surgery, Neoadjuvant Treatment Trial in Zhengzhou (Neoadjuvant immunochemo)

          Recruiting
          • Esophageal Cancer
          • +3 more
          • Neoadjuvant immunochemotherapy
          • Zhengzhou, Henan, China
            Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzh
          Oct 2, 2022

          Locally Advanced or Metastatic Solid Tumors Trial in Beijing (MSC-IFNa, Nab paclitaxel, Cyclophosphamide)

          Recruiting
          • Locally Advanced or Metastatic Solid Tumors
          • MSC-IFNα
          • +3 more
          • Beijing, China
            Department of Biotherapeutic, Chinese PLA General Hospital
          Jan 29, 2023

          T-cell-prolymphocytic Leukemia Trial in Cologne (Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab, Alemtuzumab)

          Completed
          • T-cell-prolymphocytic Leukemia
          • Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
          • Alemtuzumab
          • Cologne, Germany
            University Hospital Cologne
          Dec 16, 2021

          Follicular Lymphoma Trial in Italy (Immunochemo regimen: Rituximab-bendamustine (Arm A), Immunochemo regimen:

          Recruiting
          • Follicular Lymphoma
          • Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)
          • +9 more
          • Barletta, Barletta Andria Trani, Italy
          • +68 more
          Oct 13, 2022

          Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

          Not yet recruiting
          • Advanced Diffuse Large B-Cell Lymphoma
          • +2 more
          • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
          • Radiotherapy beyond standard R-CHOP Chemotherapy
          • (no location specified)
          May 24, 2023

          Mantle Cell Lymphoma Trial in Warszawa, Wroclaw (Obinutuzumab)

          Terminated
          • Mantle Cell Lymphoma
          • Warszawa, Poland
          • +1 more
          Dec 23, 2021

          Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

          Active, not recruiting
          • Acute Myelogenous Leukemia
          • Myelodysplastic Syndrome
          • Gemtuzumab Ozogamicin
          • Valhalla, New York
            New York Medical College
          Nov 11, 2021